[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![PrismMarketView Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1257318598386696195.png) PRISM MarketView [@PrismMarketView](/creator/twitter/PrismMarketView) on x 4696 followers
Created: 2025-07-18 11:07:59 UTC

Mesoblast (Nasdaq: $MESO) is up XX% premarket after reporting $13.2M in first-quarter sales of Ryoncil, its FDA-approved cell therapy for pediatric SR-aGvHD.

With broad U.S. coverage now in place and more transplant centers coming online, the commercial launch is gaining momentum. .@MesoblastNews


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1946165047329243640/c:line.svg)

**Related Topics**
[momentum](/topic/momentum)
[$132m](/topic/$132m)
[$meso](/topic/$meso)
[nasdaq](/topic/nasdaq)
[prism](/topic/prism)

[Post Link](https://x.com/PrismMarketView/status/1946165047329243640)